TY - JOUR
T1 - Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections-proceedings and data from the gram-negative resistance summit
AU - Kollef, Marin H.
AU - Golan, Yoav
AU - Micek, Scott T.
AU - Shorr, Andrew F.
AU - Restrepo, Marcos I.
N1 - Funding Information:
Potential conflicts of interest. Yoav Golan, MD: is on the speakers’ bureau for Merck, Pfizer, and Cubist; received grants and/or research support from Merck, Cubist, Pfizer, Astellas, and Johnson & Johnson; is a consultant for Merck, Pfizer, and Cubist. Marin Kollef, MD: is on the speakers’ bureau for Merck, Pfizer, Astellas, Sanofi Pasteur, and AstraZeneca. Scott Micek, PharmD: no reported conflicts or financial disclosures. Marcos Restrepo, MD: is on the speakers’ bureau for Covidien; received grant and/or research support from the National Heart, Lung, and Blood Institute; is also a consultant for Ortho-McNeil-Janssen (Johnson & Johnson), Forest Laboratories, Novartis, Theravance, and Pfizer (Wyeth). Andrew Shorr, MD: is on the speakers’ bureau for Astellas, AstraZeneca, Boehringer Ingleheim, Covidien, and Pfizer; received grants and/or research support from Astellas, GlaxoSmithKline, and Pfizer; is a consultant for Astellas, Bayer, Bard, Cadence Pharmaceuticals, Canyon Pharmaceuticals, Johnson & Johnson, Eli Lilly and Company, Eisai Pharmaceuticals, Forest Laboratories, MedCo, and Theravance.
Funding Information:
Supplement sponsorship. This article was published as part of a supplement entitled ‘‘Appraising Contemporary Strategies to Combat Multidrug Resistant Gram-Negative Bacterial Infections–Proceedings and Data From the Gram-Negative Resistance Summit,’’ jointly sponsored by the University of Colorado School of Medicine and Consensus Medical Communications and is supported by an educational grant from Ortho-McNeil Janssen Scientific Affairs, LLC.
Funding Information:
Financial support. This work was supported by Consensus Medical Communication (consulting fees and travel support to M. H. K., Y. G., S. T. M., M. I. R.; payment for the development of educational presentations to S. T. M.; payment for writing manuscript to all authors); Merck (payment for lectures to M. H. K. and Y. G., manuscript preparation to M. H. K., and consultancy to Y. G.; grant support to Y. G.); Pfizer (Wyeth) (payment for lectures to M. H. K., Y. G., and M. I. R.; payment for manuscript preparation to M. H. K.; payment for consultancies to Y. G. and M. I. R.; grant support to Y. G. and S. T. M.); Astellas (payment for lectures and manuscript preparation to M. H. K., grant support to Y. G.); Sanofi Pasteur and Astrazeneca (payment for lectures and manuscript preparation to M. H. K.); Cubist (grant support to Y. G. and S. T. M.; payment for lectures to Y. G.); Vernco MedEd (payment for the development of educational presentations to S. T. M.); Ortho-McNeil-Janssen (Johnson & Johnson) (payment for board membership and consultancy to M. I. R.; grants to Y. G. and S. T. M.); Therafan (payment for board membership and consultancy to M. I. R.); Forest Laboratories and Novartis (payment for board membership to M. I. R.); TRIUS (payment for consultancy to M. I. R.); Covidien and BARD (payment for lectures to M. I. R.). M. I. R. is supported and his time partially protected by a grant from the National Heart, Lung, and Blood Institute (award no. K23HL096054).
PY - 2011/9/15
Y1 - 2011/9/15
N2 - The emerging problem of antibiotic resistance, especially among Gram-negative bacteria (GNB), has become a serious threat to global public health. Very few new antibacterial classes with activity against antibiotic-resistant GNB have been brought to market. Renewed and growing attention to the development of novel compounds targeting antibiotic-resistant GNB, as well as a better understanding of strategies aimed at preventing the spread of resistant bacterial strains and preserving the efficacy of existing antibiotic agents, has occurred. The Gram-Negative Resistance Summit convened national opinion leaders for the purpose of analyzing current literature, epidemiologic trends, clinical trial data, therapeutic options, and treatment guidelines related to the management of antibiotic-resistant GNB infections. After an in-depth analysis, the Summit investigators were surveyed with regard to 4 clinical practice statements. The results then were compared with the same survey completed by 138 infectious disease and critical care physicians and are the basis of this article.
AB - The emerging problem of antibiotic resistance, especially among Gram-negative bacteria (GNB), has become a serious threat to global public health. Very few new antibacterial classes with activity against antibiotic-resistant GNB have been brought to market. Renewed and growing attention to the development of novel compounds targeting antibiotic-resistant GNB, as well as a better understanding of strategies aimed at preventing the spread of resistant bacterial strains and preserving the efficacy of existing antibiotic agents, has occurred. The Gram-Negative Resistance Summit convened national opinion leaders for the purpose of analyzing current literature, epidemiologic trends, clinical trial data, therapeutic options, and treatment guidelines related to the management of antibiotic-resistant GNB infections. After an in-depth analysis, the Summit investigators were surveyed with regard to 4 clinical practice statements. The results then were compared with the same survey completed by 138 infectious disease and critical care physicians and are the basis of this article.
UR - http://www.scopus.com/inward/record.url?scp=80052221556&partnerID=8YFLogxK
U2 - 10.1093/cid/cir475
DO - 10.1093/cid/cir475
M3 - Article
C2 - 21868447
AN - SCOPUS:80052221556
VL - 53
SP - S33-S55
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - SUPPL. 2
ER -